Kaifeng Central Hospital
14
6
6
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
The Chinese Familial Alzheimer's Network
Role: collaborator
Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis
Role: collaborator
China Cognition and Aging Study
Role: collaborator
New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China
Role: collaborator
BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
Role: collaborator
CAV Regimen for R/R AML
Role: collaborator
Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders
Role: collaborator
A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients
Role: collaborator
Clinical Study on the Safety of Double and a Half Layered Esophagojejunal Anastomosis in Curative Gastrectomy
Role: collaborator
An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovascular Diseases
Role: collaborator
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
Role: collaborator
HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population
Role: collaborator
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
Role: collaborator
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
Role: collaborator
All 14 trials loaded